Suven Life Sciences DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	1.00×	1.00×	1.00×	0.99×	1.00×
	0.95×	0.95×	0.94×	0.79×	0.89×
	−4,228.1%	−4,077.7%	−2,578.1%	−1,150.3%	−978.1%
	0.02×	0.02×	0.03×	0.03×	0.05×
	1.06×	1.06×	1.23×	1.06×	1.04×
	−84.4%	−82.0%	−89.1%	−28.4%	−45.3%
	−78.8%	−78.8%	−84.6%	−32.6%	−50.2%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUVEN₹264.20

Suven Life Sciences Limited

· Pharma & Health

₹ CrorePeersVIMTALABS TAKEMcap ₹6,967 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	1.00	0.99	1.00	1.00	1.00
Interest Burden (Pretax/EBIT) ×	0.89	0.79	0.94	0.95	0.95
EBIT Margin %	-978.11	-1,150.33	-2,578.13	-4,077.70	-4,228.11
Asset Turnover ×	0.05	0.03	0.03	0.02	0.02
Financial Leverage (Assets/Equity) ×	1.04	1.06	1.23	1.06	1.06
ROE (5-step product, year-end total equity) %	-45.26	-28.44	-89.05	-81.99	-84.41
ROE (owners' profit / average owners' equity) %	-50.17	-32.56	-84.60	-78.80	-78.80

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.